Hookipa Pharma Inc. Stock News

HOOKIPA Pharma Inc. (NASDAQ:HOOK ) Q4 2022 Results Conference Call March 15, 2023 8:30 AM ET Company Participants Matthew Beck - Executive Director, Investor Relations Joern Aldag - Chief Executive Of

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 5.56% and 41.25%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

NEW YORK and VIENNA, March 08, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus plat

NEW YORK and VIENNA, Austria, Feb. 07, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavi

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of -4.17% and 31.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock

NEW YORK and VIENNA, Austria, Nov. 07, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapies based on its proprietary arenavirus

Use these tips for finding popular penny stocks to buy right now The post How to Find Popular Penny Stocks Right Now  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.

Hookipa (NASDAQ: HOOK ) stock is rocketing higher on Thursday after reaching a strategic collaboration and license agreement with Roche (OTCMKTS: RHHBF ). That agreement has the two companies working

HOOKIPA Pharma Inc. (HOOK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

NEW YORK and VIENNA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapies based on its proprietary arenavirus platfor

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 36.11% and 21.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 36.11% and 21.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) delivered earnings and revenue surprises of -12.50% and 8.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 14.75% and 7.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -29.41% and 30.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?